Selected patients with Myelodysplastic Syndromes (MDS) are responsive to immunosuppressive therapy, suggesting that hematopoietic suppressive T cells have a pathogenic role in ineffective hematopoiesis. We assessed T-cell receptor (TCR) clonality through combined flow cytometry and molecular analysis of the complementarity determining region (CDR)-3 of the T-cell receptor-Vb gene. We identified clonal T cells in 50% of MDS patients (n ¼ 52) compared to 5% of age-matched normal controls (n ¼ 20). The presence of T-cell clones was not associated with features linked previously to immunosuppression response, including WHO diagnostic category, karyotype, marrow cellularity, IPSS category, sex or age p60. Using flow cytometry to identify expanded Vb-families, we found that T cells showed greater expansion in the bone marrow compared with peripheral blood, and were characterized as CD8 þ /CD57 þ /CD28 À effector T cells. Expanded effector T cell were CD62L negative and expressed the natural killer C-lectinfamily receptor NKG2D and CD244 (2B4). We conclude that clonal T-cell expansion is common among all MDS prognostic subgroups.
Introduction
The Myelodysplastic Syndromes (MDS) comprise a spectrum of stem cell malignancies that are responsive to a wide range of mechanistically diverse treatment interventions. 1 Despite improvements in pathologic classification schemes to define patients at greater risk for leukemia transformation and poor survival, disease-specific treatment algorithms are inadequately delineated. Three agents were recently approved by the Food and Drug Administration (FDA) for the treatment of MDS that include the hypomethylating agents, 5-azacytadine (Vidaza, Pharmion, Corp., San Francisco, CA, USA) and decitabine (Dacogen, MGI Pharma Inc., Bloomington, MN, USA), and the immunomodulatory drug lenalidomide (Revlimid, Celgene Corp., Summit, NJ, USA). 2, 3 Investigations of immunosuppressive therapies have shown that a subset of MDS patients experience sustained erythroid improvement with response rates ranging from 15 to 45%. [4] [5] [6] [7] [8] [9] [10] [11] [12] Univariant and multivariant statistical analyses have identified clinical and biological features associated with clinical response to immunosuppressive therapy, which served as the basis for the generation of response predictive models. [4] [5] [6] [13] [14] [15] [16] [17] [18] In these analyses, bone marrow hypocellularity, HLA-DR15 phenotype, younger age, lower platelet count and shorter duration of transfusion requirement were associated with response to immunosuppressive therapy. 5, 14, 19 Analogous to aplastic anemia, elimination of a hematopoietic suppressor T-cell population is hypothesized to underlie treatment response to immunosuppression in this subset of MDS patients. 16, 20 Clonal T cells in both MDS and AA can be identified through analysis of the complementarity determining region (CDR)-3 of the T-cell receptor (TCR), which directly binds to antigenic peptides presented in the context of HLA. Gene rearrangement of different V, D, J and C regions leads to the assembly of highly diverse receptors with varying lengths. 21 An increased proportion of T cells with a restricted CDR-3 TCR-Vb nucleotide length, which is representative of clonal T-cell expansion, is known as 'TCR-Vb-repertoire skewing'. [22] [23] [24] [25] In normal T-cell homeostasis, a limited number of clones undergo periodic expansion in response to foreign antigens. However, exaggerated clonal T-cell expansion is associated with viral infections, autoimmune diseases and clonal T-cell malignancies. [26] [27] [28] [29] [30] A classic example of antigen-targeted clonal T-cell expansion occurs in patients with large granular lymphocyte leukemia (LGLL), which is characterized by massive clonal expansion of CD8 þ T cells with a restricted CDR3-TCR-Vb nucleotide length. 24, 27 Current consensus suggests that the expanded T-cell clones in MDS patients have a pathogenetic role in hematopoietic suppression and that their elimination is essential for hematopoietic improvement.
Although depletion of clonal T cells has been reported in isolated MDS cases responding to immunosuppressive treatment, the prevalence of T-cell clonality and function has not been widely investigated. Moreover, immunosuppression response models suggest that such patients may represent a distinct subpopulation characterized by increased frequency of pathologic T-cell clones when compared to MDS patients at large. To define further the role of T-cell pathology in MDS, we (1) assessed the frequency of clonal T-cell expansion in MDS patients using TCR-CDR3-Vb size distribution compared to normal controls, (2) quantified the number of T cells in each Vb-family that are expanded in the peripheral blood and bone marrow and (3) investigated the clinical characteristics associated with TCR-CDR3-Vb skewing.
Patients, materials and methods

Patients and preparation of PBMCs
Fifty-two patients with MDS defined by the WHO classification scheme provided informed consent for the study. International Prognostic Scoring System (IPSS) risk score and category was characterized according to published criteria. 31 Patient age ranged from 42 to 83 years (median age 69). Bone marrow and peripheral blood were compared in nine patients. Peripheral blood was obtained from buffy coats from 20 normal healthy donors that donated blood at the Southwest Florida Blood Services. Age distribution of normal donors included 10 younger donors that ranged from 18 and 25 years, and 10 donors ranging from 55 to 85 years of age. Bone marrow mononuclear cells (BM-MNCs) and peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque gradient separation, as described previously. 32 
Multiplex TCR-Vb (CDR3) PCR analysis
We performed multiplex TCR-Vb (CDR3) PCR on genomic DNA from PBMCs of MDS patients compared to normal donors. DNA was prepared from 1 Â 10 7 PBMCs using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA). Each of the Vb families were amplified by nested PCR, as described previously. 33, 34 To enhance the detection of clonally expanded cells, Cy5-labeled primers were used and the length of the PCR products was analyzed on an ABI Prism. 33, 34 These assays were performed in collaboration with the Tampa General Hospital Laboratory of Esoteric Testing, Tampa, FL, which is a clinically certified laboratory for the detection of T-cell malignancies using these methods. A positive clonal population of T cells was indicated by a single peak with a height threefold or greater above background polyclonal peaks. 24 Flow cytometric analysis of Vb usage and phenotype analysis We calculated the expansion index above normal using the following equation: expanded T-cell populations were defined as Vb-families with three times the s.d. of the mean of the control group that ranged from 55 to 85 years old. Simultaneous staining for additional surface markers on the expanded Vb-families was also performed by flow cytometry. Antibodies defined CD4 and CD8 T-cell subpopulations (anti-CD4-and anti-CD8-APC) and the expanded Vb þ cells were examined for the expression of CD57, NKG2D, CD244, CD28, CD69, CD62L and CD25 with antibodies conjugated to PE (BD Biosciences).
Statistical analysis
The relationship between clonal T-cell expansion and clinical characteristics were analyzed by varied methods. Means and s.d. for clinical characteristics expressed as continuous variables (age, hemoglobin level, neutrophil count, platelet count, lymphocyte count) were calculated for TCR-positive and TCR-negative patients. To account for the skewed distributions of these variables, they were compared across the two groups of patients using the Wilcoxon rank sum test. Age was also categorized into o61 years and X61 years, as these categories have been shown previously to predict immunosuppressive therapeutic responses. 19 The percent of patients positive for clonal T-cell expansion was calculated for each of the two age groups and compared using the w 2 test. Similar analyses were conducted for other clinical characteristics expressed as categorical variables including sex, WHO classification, IPSS risk and transfusion history at diagnosis, bone marrow cellularity and karyotype. P-values were obtained using Fischer's exact test when frequencies were less than five. The Mantel-Haenszel w 2 test for trend was used to assess statistical significance of the associations between clonal T-cell expansion and clinical characteristics expressed as ordered categories (IPSS risk score/ category and number of transfusions). In order to identify expansion of a given TCR-Vb family, individual values were compared to the distribution of the older normal control group. Values were considered abnormal when expressed at greater than the mean þ 3 Â s.d. of the older normal control group.
Results
Incidence of clonal T-cell expansion in MDS patients and controls by Vb (CDR3) multiplex PCR
Multiplex PCR was performed to amplify the TCR-CDR3-Vb region shown in Figure 1a . A typical clonal T-cell peak detected by this PCR method is shown for a single MDS patient compared to a normal control ( Figure 1a) . We estimated the sensitivity of this assay in Jurkat T cells (a clonal T-cell leukemic cell line) using PBMCs from a normal individual mixed with varying amounts of Jurkat cells (TCR-Vb12-positive). We found that positive clonal peaks could be detected at a sensitivity of one in 100 cells using two different primer mixes capable of detecting TCR-Vb12 (Figure 1b , primer mix A and C). As expected, the PCR-primer mix B failed to detect clonal Jurkat cells (data not shown).
Peripheral blood mononuclear cells (PBMCs) from 52 MDS patients and 20 normal donors analyzed by multiplex PCR amplification of the TCR-CDR3 region were compared for Vb-family skewing (as shown in Figure 1a ). WHO disease categories included refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory cytopenia with multilineage dysplasia (RCMD), RCMD with ringed sideroblasts (RCMD-RS), refractory anemia with excess blasts (RAEB) 1 and 2, chronic myeloid monocytic leukemia (CMML) and AML that arose from a background of MDS. Four patients with MDS had progressed to AML at the time of sample acquisition. Clonal T-cell expansions were detected in only one of 20 healthy individuals (5%) in a single donor in the older normal group. In contrast to normal controls, clonal T cells were identified in 26 of 52 MDS patients (50%) (Po0.0001 using w 2 analysis).
Clinical characteristics of MDS patients with clonal T cells
To characterize the subset of MDS patients with clonal T cells, clinical characteristics of these patients were compared to those without clonal T cells (Table 1) . Patients with clonal T cells tended to be older, have lower hemoglobin level, higher neutrophil count and lower platelet count, although none of these associations were statistically significant. No differences in the presence of clonal T cells were observed according to lymphocyte count, gender or age. The frequency of clonal T-cell expansion increased incrementally with IPSS risk category, although this trend was not statistically significant. Extensive prior exposure to allogeneic antigens through multiple transfusions was not associated with a higher frequency of clonal T-cell expansion. Compared to patients with excess blasts (EB), including those with RAEB1, RAEB2 and AML, patients with RA were more likely to have T-cell clones, and patients with RCMD had a lower relative frequency of T-cell clones (62.5 RA vs 41.7% RCMD vs 55% EB, respectively). Two patients were classified as RARS and clonal T cells were detected in one of these patients. Seven of 24 RCMD patients had RCMD-RS. Four out of seven of the RCMD-RS patients had clonal T cells. Therefore, the presence of ringed sideroblasts within the RA and RCMD groups did not impact clonal T cells frequency.
Relation between bone marrow pathology and presence of clonal T-cell expansion in the peripheral blood
Bone marrow was categorized as hypocellular, normal cellular and hypercellular relative to normal age-matched controls, as described previously (Table 2) . 35 Patients with age-adjusted hypocellularity, in this case series, had a similar frequency of clonal T cells compared to patients with normal cellularity (P ¼ 0.66, Table 2 ). Some specific abnormal karyotypes have been associated with higher risk for leukemic progression in previous studies. 36 The presence of an abnormal karyotype including trisomy 8, has been specifically linked to both response to immune suppression and the presence of clonal T cells. 6, 37 Although the number of patients with each individual chromosome abnormality was small, all patients with monosomy 20 (3 out of 3) and most with monosomy seven (3 out of 4) had clonal T cells demonstrable in the peripheral blood (Table 2) , whereas only one of four patients with trisomy 8 had clonal T-cell expansions.
Detection of expanded Vb families by flow cytometry
Antigen-driven expansion of T-cell clones leads to an increased frequency of Vb families by flow cytometry. 38 Using flow cytometry, T cells were positively selected by gating on anti-CD3 þ cells and the percentage of T cells in each Vb-family determined in normal individuals. We found that the percentage of each Vb-family in our reference group did not differ from published reports of 85 normal donors. (reference group published by Beckman Coulter, Fullerton, CA, USA) Furthermore, the frequency of each Vb-family did not differ in the older (n ¼ 7) and younger normal controls (n ¼ 6) (data not shown). Expansion of a given Vb-family was considered abnormal when expressed at the mean þ 3 Â s.d. of the older normal control group. We performed flow cytometry on samples obtained from each of the MDS patients (n ¼ 21) with clonal T cells by TCR-CDR3-Vb genomic analysis. Table 3 shows the percentage of CD3 þ /Vb þ cells in each of the expanded Vb families in these MDS patients. Eighteen of the 21 patients had expanded T-cell populations by flow cytometry ranging from 1 to 8 different Vb-families. Vb-11 was expanded in five patients, which was the most frequent, and Vb-1, Vb-9, Vb-18 and Vb-23 were all expanded in four patients. Other Vb-families were expanded in one to three patients (Vb-4, 5.2, 7.1, 7.2, 13.1, 13.6, 14, 17 and 21.3). The bone marrow is hypothesized to be the site where neoplastic antigen triggers expansion of hemosuppressive T cells. [39] [40] [41] In seven patients, we compared the magnitude of Vb-expansion in the bone marrow and peripheral blood using flow cytometry. Figure 2 shows the percentage of T cells positive for each of the Vb-families that were expanded. We consistently observed greater expansion of Vb families in the bone marrow compared to the peripheral blood. The bone marrow harbored expanded Vb-families that were not present in the peripheral blood, as seen in MDS donors 54, 22, 27, 33 and 19) and/or an increased percentage of cells within a given Vb-family (MDS donor 27). One of the seven patients showed no increase in expanded Vb-families in the bone marrow. These data indicate that T cells display greater expansion in the bone marrow in MDS patient.
Phenotype analysis of expanded Vb-families
A model of T-cell-mediated immune suppression suggests that uniquely aggressive autoreactive clonal T cells promote suppression of hematopoiesis. Previous results have shown that expanded T-cell populations in MDS have a CD8
þ effector phenotype with expression of CD57, loss of the co-stimulatory molecule CD28, and overexpression of perforin or granzyme. 17 We compared the surface markers expressed by clonal T cells and non-clonal T cells within the same patient. Similar to previous data, we found that all expanded T cells in MDS patients were CD8 þ cytotoxic cells. 17 We compared CD8 þ T cells in MDS and normal controls. Of the surface markers studied, we found that expression of HLADR, CD25 and CD69 on patient CD8 þ T cells did not differ from normal controls (Table 4) . CD28 was significantly reduced on CD8 þ T cells from MDS patients (71.8%711.7 in controls vs 26.5%711.8, Po0.001 by pooled t-test); whereas, CD57 was increased (21.3%79.1 in controls vs. 37%78, P ¼ 0.03 by a pooled t-test). As described previously in autoimmune diseases such as LDGL and rheumatoid arthritis, the NK activating receptors 
Discussion
Oligoclonal or monoclonal T-cell expansion is associated with lymphocyte-associated suppression of myelopoiesis in diseases such as aplastic anemia, LDGL, paroxysmal-nocturnal hemaglobinuria (PNH), and MDS. 17, [23] [24] [25] 30, 45 Expansion of these pathologic T-cell populations may reflect an underlying autoimmune, antigen-driven process. 25, 45 We studied a cohort of 52 patients for the presence of clonal T-cell expansion using combined molecular and flow cytometric methods. We confirmed that CD8 þ /CD57 þ /CD28 -effector T cells are commonly expanded in patients with MDS compared to agematched controls.
4,17 Furthermore, we found that the CD8 þ T cells and T-cell clones from MDS patients express NKG2D and CD244 (2B4), which are activating NK receptors that provide co-stimulation and induce effector functions in T lymphocytes. [46] [47] [48] [49] Unlike traditional mechanisms of antigen co-stimulation with anti-CD28, expression of these molecules on CD8 þ T cells may play an active role in promoting autoimmune disease. 50, 51 The ligand for CD244 (2B4), CD48, is expressed on hematopoietic stem cells. 49, 52 CD244-deficient mice lack multiple effector functions and CD244-CD48 interactions produce more efficient lysis than classical CD8
þ T cells pathways. 53 Effector functions associated with CD244 activation in CD8
þ T cells include induction of granzyme B and perforin expression, rapid interferon (IFNg) production, and downregulation of a lymph node homing receptor, CCR7. We also found that the lymph node homing receptor, CD62L which is often co-expressed with CCR7, was under-represented in CD8 þ lymphocytes and on clonal T cells from MDS patients coincident with greater marrow lymphocyte expansion. The distinct receptors that trigger bone marrow homing are not well defined but memory T cells display preferential homing capacity over naïve cells when adoptively transferred into normal young mice. 54 Expression of CD244 and an increased capacity for bone marrow homing or migration could be important in disease pathology. Further studies are necessary to characterize the molecules mediating T-cell migration, bone marrow homing and the mechanism of T-cell activation in MDS patients.
Elimination of a hematopoietic suppressor T-cell population is proposed to underlie treatment response to immunosuppression in responsive MDS patients. Variables previously linked to clinical response to immune suppression include bone marrow hypocellularity, presence of HLA-DR15 expression, younger age, lower platelet count, blast percentage and shorter duration of transfusion requirement, which are primarily features associated with favorable prognosis. 5, 13, 14, 18, 19, 55, 56 The presence of clonal T cells was not significantly associated with any of the clinical factors examined, although there was a slight positive trend with increasing IPSS risk category. Multivariable analyses were limited by small sample size, thus, our data do not preclude the possibility that multiple clinical factors combined may be more strongly associated with immunologic activation than any single factor. Our findings, if confirmed, suggest that immunosuppressive therapy may warrant investigation in select higher risk MDS patients if such clonal T-cell populations have a pathogenic role in myeloid maturation. Monosomy 7 and monosomy 20 are generally considered karyotypes associated with less immunogenicity and poorer prognosis than other cytogenetic abnormalities, especially when compared previously to patients with trisomy 8 mutations.
7,37 A cohort of 34 MDS patients with trisomy 8 were found to have extensive CD8
þ T-cell expansion that inhibited trisomy 8 positive myeloid colonies growth in vitro. 6, 37 Of these 34 patients, 28 exhibited trisomy 8 as a sole mutation and an additional three patients displayed trisomy 8 in conjunction with either 5q-or monosomy 20. Only three patients had coincident trisomy 8 and monosomy 7. Two patients out of seven with monosomy 7, in the absence of trisomy 8, responded to immunosuppression. In our series of patients, the sample sets for each individual mutation were small and two of the four patients with trisomy 8 had complex abnormalities. In 52 diverse MDS patients, we found no association between clonal T-cell expansion and disease characteristics. We also found that most patients had several Vb-families that were expanded. Our findings indicate that expansion of T-cell clones is not restricted to specific IPSS or WHO subtypes, younger age, transfusion history or karyotype and suggest that the aberrant immune response and relationship between skewed TCR repertoires and immunosuppressive responses should be clarified in MDS.
